Qikuan He

Qikuan He

Auto-generated profile, based on publicly available information

Qikuan He

Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Purpose: We aimed to construct machine learning (ML) radiomics models to predict response to lenvatinib monotherapy for unresectable hepatocellular carcinoma (HCC). Experimental Design: Patients with HCC receiving lenvatinib monotherapy at three institutions were retrospectively identified and assigned to training and external validation cohorts. Tumor response after initiation of lenvatinib was evaluated. Radiomics features were extracted from contrast-enhanced CT images. The K-means clustering algorithm was used to distinguish radiomics-based subtypes. Ten ML radiomics models were constructed and internally validated by 10-fold cross-validation. These models were subsequently verified in an external validation cohort. Results: A total of 109 patients were identified for analysis, namely, 74 in the training cohort and 35 in the external validation cohort. Thirty-two patients showed partial response, 33 showed stable disease, and 44 showed progressive disease. The overall response rate (ORR) was 29.4%, and the disease control rate was 59.6%. A total of 224 radiomics features were extracted, and 25 significant features were identified for further analysis. Two distant radiomics-based subtypes were identified by K-means clustering, and subtype 1 was associated with a higher ORR and longer progression-free survival (PFS). Among the 10 ML algorithms, AutoGluon displayed the highest predictive performance (AUC = 0.97), which was relatively stable in the validation cohort (AUC = 0.93). Kaplan–Meier analysis showed that responders had a better overall survival [HR = 0.21; 95% confidence interval (CI): 0.12–0.36; P < 0.001] and PFS (HR = 0.14; 95% CI: 0.09–0.22; P < 0.001) than nonresponders. Conclusions: Valuable ML radiomics models were constructed, with favorable performance in predicting the response to lenvatinib monotherapy for unresectable HCC.

19 December 2024 in Cancer Medicine
Verified
Journal Article
Open access
BHBingren Hu
Bingren Hu
YYYi Yang
Yi Yang
JYJiangqiao Yao
Jiangqiao Yao
GLGanglian Lin
Ganglian Lin
QHQikuan He
Qikuan He
YSYunfeng Shan
Yunfeng Shan
Background: The impact of gut microbiome on hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) is unclear. We aimed to evaluate the potential correlation between gut microbiome and HBV‐related HCC and introduced novel machine learning (ML) signatures based on gut microbe to predict the risk of HCC.Materials and Methods: A total of 640 patients with chronic liver diseases or HCC were prospectively recruited between 2019 and 2022. Fecal samples were collected and subjected to 16S rRNA gene sequencing. Univariate and multivariate logistic regression was applied to identify risk characteristics. Several ML methods were employed to construct gut microbe‐based models and the predictive performance was evaluated.Results: A total of 571 patients were involved in the study, including 374 patients with HCC and 197 patients with chronic liver diseases. After the propensity score matching method, 147 pairs of participants were enrolled in the analysis. Bacteroidia and Bacteroidales were demonstrated to exert mediating effects between HBV and HCC, and the moderating effects varied across Bacilli, Lactobacillales, Erysipelotrichaceae, Actinomyces, and Roseburia. HBV, alpha‐fetoprotein, alanine transaminase, triglyceride, and Child‐Pugh were identified as independent risk factors for HCC occurrence. Seven ML‐based HBV‐gut microbe models were established to predict HCC, with AUCs ranging from 0.821 to 0.898 in the training set and 0.813–0.885 in the validation set. Furthermore, the merged clinical‐HBV‐gut microbe models exhibited a comparable performance to HBV‐gut microbe models.Conclusions: Gut microbes are important factors between HBV and HCC through its potential mediating and moderating effects, which can be used as valuable biomarkers for the pathogenesis of HBV‐related HCC.

1 April 2023
Verified
Other
Open access
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Essential scripts for each model and the specific parameters of the models.

1 April 2023
Verified
Other
Open access
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Baseline characteristics between patients with unresectable HCC treated with lenvatinib in the training and external validation cohort.


1 April 2023
Verified
Other
Open access
ZBZhiyuan Bo
Zhiyuan Bo
BCBo Chen
Bo Chen
ZZZhengxiao Zhao
Zhengxiao Zhao
QHQikuan He
Qikuan He
YMYicheng Mao
Yicheng Mao
GCGang Chen
Gang Chen
Comparison of predictive value of 10 machine learning algorithms for predicting the response to lenvatinib in the training and external validation cohorts.